Form 4: Cytokinetics Director Robert E. Landry Acquires Stock Options
SEC Form 4 Filing
Robert E. Landry, a director of Cytokinetics Inc., was granted stock options to purchase 25,538 shares of common stock.
Summary
- On February 10, 2025, Robert E. Landry, a director at Cytokinetics Inc., received an initial grant of non-qualified stock options.
- These options allow him to purchase 25,538 shares of Cytokinetics' common stock at an exercise price of $42.21 per share.
- The options vest monthly over a 3-year period from the grant date and expire on February 12, 2035.
- Following this transaction, Landry directly owns 25,538 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the company's future prospects and aligns the director's interests with shareholders.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of monthly over 3 years is a typical arrangement to incentivize long-term commitment.
- Comparable companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with increasing shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of the stock option grant to Robert E. Landry. |
| 02/11/2025 | Date of signature by attorney-in-fact for Mr. Landry. |
| 03/10/2025 | Start date of monthly vesting period. |
| 02/12/2035 | Expiration date of the stock options. |
Keywords
stock options, director, Cytokinetics, Form 4, beneficial ownership, equity securities, Robert E. Landry
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.